Clinical Trials

Inclusion Criteria: 

• Age ≥ 18 years
• Complete surgical staging at Mayo Clinic (MCR, MCA, MCF). Complete surgical staging includes at least total hysterectomy, bilateral salpingo-oophorectomy and lymph node assessment. Sentinel node mapping meets the criteria for lymph node assessment. Peritoneal cytology is recommended. Additional staging procedures such as pelvic and para-aortic nodal evaluation, omental biopsy or omentectomy, may also be utilized for staging in patients based on the clinical situation and at the surgeon’s discretion.
• At least one preoperative or postoperative feature of aggressive disease (FIGO staging used throughout this protocol)
  • Preoperatively:
    • Biopsy with grade 3 endometrioid EC or non-endometrioid EC
    • Patients with FIGO grade 1-2 EC with evidence of extra-uterine disease on imaging (CT, MRI, or PET)
  • Postoperatively:
    • Endometrial cancer (FIGO) with one or more established risk factors:
      • Non-endometrioid histology
      • Grade 3
      • Lymphovascular space invasion (LVSI), ≥50% of myometrial invasion, presence of isolated tumor cells (ITC) in a sentinel lymph node
      • Stage II to IV (FIGO) EC
• Provide written informed consent

• Willingness to provide mandatory blood specimens for correlative research (see Section 14.0).

• Willingness to provide mandatory tissue specimens for correlative research (see Section 17.0).

• Willingness to return to registering site for clinical follow-up.

Exclusion Criteria: 

• Patient receiving or who has received neoadjuvant chemotherapy
• Pre-operative population pregnant not an option

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 1/23/2025. Questions regarding updates should be directed to the study team contact.